Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Rick Costantino who wrote (1361)	1/30/1998 3:14:00 PM
From: Rick Strange	Read Replies (1) \| Respond to of 2205

Rick, I just want to add my own two-bits to your comments about "investing in technology to satisfy unmet medical needs and improve the quality of life." During the public comment portion of the panel presentation for Dermagraft, two of the people urging recommendation were two people that had had their diabetic ulcers healed using the product. One was Frank J. Baker, M.D., former Professor and Chairman of the Department of Emergency Medicine, University of Chicago. Frank had been bitten by a brown recluse spider. Because he was diatetic the wound failed to heal, it became infected and he had several toes amputated. Because of the change of his gait he developed a diabetic foot ulcer that refused to heal. In April of 1997 he was granted a Compassionate Use Waver and treated with Dermagraft. "The response was nothing short of amazing. Two days after the first application, my physician and I could see an obvious improvement in my wound. Another was Mrs. Sullivan. She was there because she had been told that it was a question of time before she lost her leg if they couldn't get her ulcer to heal. I know that this sounds like so much corn but I was very proud that my small investment helped these two people WALK to the podium and STAND there to tell their story. One more impression. I had been forewarned what a dynamo we had in Gail Naughton, president and C.O. of ATIS. She is a wonder to behold. I feel very comfortable with her at the helm. I think she knows how to navigate to where we want to go.

To: Rick Costantino who wrote (1361)	1/31/1998 1:13:00 AM
From: Marshall Teitelbaum	Read Replies (1) \| Respond to of 2205

Hi Rick, Sometimes it seems you, Bill, Rick S,Jack, and a few others will all grow old together here awaiting news, but it truly has been enjoyable, given the team effort, information shared, and the different educated opinions offered....not to mention, you have all been gentlemen. It sure looks like ATIS is finally starting to realize its goals as they begin to reach the point where products are no longer only up the road. People who only want to give the share price for ATIS consideration as to what the revenues for dermagraft will be(the old fashioned show me the money attitude for investing) still doesn't totally apply. They are/will be very much valued on the potential of their technology and their future products, even though some of the value will begin to be based on current products and the revenues brought in over the next few years as dermagraft gets rolling. Biotechs don't get valued over night from research to production companies unless they're one-hit wonders, or else nobody would ever buy one, as they're all way too expensive when simply based on potential and burning cash. You are so right about the rewarding feeling when science takes steps forward and allows true advances in aiding humanity. It almost makes the rationalization about our desire for profits(are we ferengi?) justifiable. :) I look forward to seeing more of your posts as we go here....hasn't been the same without you spending more time of here. Regards, Marshall